Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors

Int J Cancer. 2012 Apr 15;130(8):1937-47. doi: 10.1002/ijc.26216. Epub 2011 Aug 8.


The safety of oncolytic viruses for treatment of cancer has been shown in clinical trials while antitumor efficacy has often remained modest. As expression of the coxsackie-adenovirus receptor may be variable in advanced tumors, we developed Ad5-D24-RGD, a p16/Rb pathway selective oncolytic adenovirus featuring RGD-4C modification of the fiber. This allows viral entry through alpha-v-beta integrins frequently highly expressed in advanced tumors. Advanced tumors are often immunosuppressive which results in lack of tumor eradication despite abnormal epitopes being present. Granulocyte-macrophage colony stimulating factor (GMCSF) is a potent activator of immune system with established antitumor properties. To stimulate antitumor immunity and break tumor associated immunotolerance, we constructed Ad5-RGD-D24-GMCSF, featuring GMCSF controlled by the adenoviral E3 promoter. Preliminary safety of Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of human cancer was established. Treatments with Ad5-D24-RGD (N = 9) and Ad5-RGD-D24-GMCSF (N = 7) were well tolerated. Typical side effects were grade 1-2 fatigue, fever and injection site pain. 77% (10/13) of evaluable patients showed virus in circulation for at least 2 weeks. In 3 out of 6 evaluable patients, disease previously progressing stabilized after a single treatment with Ad5-RGD-D24-GMCSF. In addition, 2/3 patients had stabilization or reduction in tumor marker levels. All patients treated with Ad5-D24-RGD showed disease progression in radiological analysis, although 3/6 had temporary reduction or stabilization of marker levels. Induction of tumor and adenovirus specific immunity was demonstrated with ELISPOT in Ad5-RGD-D24-GMCSF treated patients. RGD modified oncolytic adenoviruses with or without GMCSF seem safe for further clinical development.

Publication types

  • Clinical Trial

MeSH terms

  • Adenoviridae / genetics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell Line, Tumor
  • DNA, Viral / genetics
  • Drug Resistance, Neoplasm
  • Fatigue / etiology
  • Female
  • Fever / etiology
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / genetics
  • Granulocyte-Macrophage Colony-Stimulating Factor / genetics
  • Granulocyte-Macrophage Colony-Stimulating Factor / metabolism*
  • Humans
  • Integrins / metabolism
  • Male
  • Middle Aged
  • Neoplasms / metabolism
  • Neoplasms / therapy*
  • Neoplasms / virology
  • Oligopeptides / genetics
  • Oligopeptides / metabolism*
  • Oncolytic Virotherapy / adverse effects
  • Oncolytic Virotherapy / methods*
  • Oncolytic Viruses / genetics
  • Real-Time Polymerase Chain Reaction
  • Treatment Outcome
  • Viral Load
  • Virus Replication / genetics


  • DNA, Viral
  • Integrins
  • Oligopeptides
  • arginyl-glycyl-aspartic acid
  • Granulocyte-Macrophage Colony-Stimulating Factor